Date Modified: May 29, Clinical Quality Measures for PQRS

Similar documents
Date Modified: March 31, Clinical Quality Measures for PQRS

Non-QPP Measures. # Measure Title Definition Type Domain. Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys

creatinine lab order placed abdomen, MRI abdomen, ultrasound abdomen ordered or performed

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

Prostate Cancer Dashboard

Cancer Endorsement Maintenance 2011-Maintenance Measures

Non-QPP Measures 3 AQUA12. 6 AQUA15 Stones: Urinalysis documented 30 days before

Percentage of patients who underwent endoscopic procedures following SWL

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures

NATIONAL QUALITY FORUM

Identifying Initial Populations and Sampling for OCM and EBRT. Henrietta C. Hight, BA, BSN, RN, CCM, CDMS, CPHQ Quality Improvement Specialist

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

One Stop Prostate Biopsy Protocol Author Consultation Date Approved

Best Papers. F. Fusco

Measure #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clincial Care

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Screening and Diagnosis Prostate Cancer

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

Case Discussions: Prostate Cancer

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

The European Board of Urology

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

THE UROLOGY GROUP

AQUA Registry 2019 Non-QPP Measure Specifications. Denominator Exceptions. IPSS<8 None None Yes Patient Reported Outcome (PRO)

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Michigan Urological Surgery Improvement Collaborative

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Troubleshooting Audio

Physician Self-Referral: Recent Research from the Government Accountability Office (GAO)

Clinical Quality Measures for PQRS. Last Updated: June 4, 2014

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Commissioning Urology Services in New NHS

IQSS 2019 QCDR and MIPS Measure Specifications

How do I control (monitor) patients receiving TRT after prostate cancer treatment

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

Prostate MRI: Who needs it?

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

Possible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436

A schematic of the rectal probe in contact with the prostate is show in this diagram.

Table 1 Standards and items to set up a PCU: general requirements and critical mass

Diagnosis and management of prostate cancer in the

2014 Oncology Measures Group Overview

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Department of Urology, Cochin hospital Paris Descartes University

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation

Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546

Prostate Cancer in men with germline DNA repair deficiency

THE HISTORY AND EVOLUTION OF PROSTATE CANCER DIAGNOSIS AND TREATMENT BY: DR. ANDREW GROLLMAN ALBUQUERQUE UROLOGY ASSOCIATES

Focal Therapy is a Fool s Paradise : The whole prostate must be treated!

Low risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer

Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

Prostate Cancer. Dr. Andres Wiernik 2017

PSA is rising: What to do? After curative intended radiotherapy: More local options?

Consensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease

Prostate Overview Quiz

PPS Exempt Cancer Hospital Quality Reporting (PCHQR) Program Relationship Matrix of Program Measures by Years and Quarters

Appendix 4 Urology Care Pathways

To treat or not to treat: When to treat! A case presentation

Prostate Cancer Case Study 2. Medical Student Case-Based Learning

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment

Meaningful Use Clinical Quality Measures for Eligible Professionals

PRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES

R-SCAN: Engaging Clinicians in Value-based Care

Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18

Prostate Cancer: 2010 Guidelines Update

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

Clinical Case Conference

PPS Exempt Cancer Hospital Quality Reporting (PCHQR) Program Relationship Matrix of Program Measures by Years and Quarters

Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease

NQF Measure Number & PQRI Implementation Number

Troubleshooting Audio

2017 Merit-based Incentive Payment System. Avoiding the Penalty

Cancer Center Dashboard

PET imaging of cancer metabolism is commonly performed with F18

[PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK

2014 AUA Annual Census

Clinical Quality Measures for Submission by Medicare or Medicaid EP/s for the 2011 and 2012 Payment Year

Detection & Risk Stratification for Early Stage Prostate Cancer

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice

Guideline Prostate cancer: diagnosis and management (update)

Attachment #2 Overview of Follow-up

Prostate Cancer Local or distant recurrence?

Newer Aspects of Prostate Cancer Underwriting

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

NPQR Quality Payment Program (QPP) Measures 21_18247_LS.

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes

Transcription:

Date Modified: May 29, 2014 Clinical Quality s for PQRS

# Domain Type Denominator Numerator Denominator Exclusions/Exceptions Rationale QCDR-1 QCDR-2 Patient Safety 102 Efficiency and Cost Reduction QCDR-3 Efficiency and Cost Reduction 104 194 250 QCDR-4 QCDR-5 QCDR-6 Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy Unplanned Hospital Admission within 30 Days of TRUS Biopsy: Percentage of biopsies where patients aged 30 years and had an unplanned hospital admission within 30 days of biopsy Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a CT scan performed at any time since diagnosis of Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients: Percentage of patients, regardless of age, with a diagnosis of at high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist) Oncology: Cancer Stage Documented: Percentage of patients, regardless of age, with a diagnosis of cancer who are seen in the ambulatory setting who have a baseline American Joint Committee on Cancer (AJCC) cancer stage or documentation that the cancer is metastatic in the medical record at least once during the 12 month reporting period Radical Prostatectomy Pathology Reporting: Percentage of radical prostatectomy pathology reports that include the pt category, the pn category, the Gleason score and a statement about margin status Prostate Cancer: Proportion of patients with low-risk receiving active surveillance Prostate Cancer: Percentage of cases with a length of stay > 2 days Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy: Percentage of patients aged 30 years and who had an unplanned hospital readmission within 30 days of principal procedure # of prostate biopsies for patients aged 30 or # of prostate biopsies for patients aged 30 or PQRS See cancer patients 30 years or receiving brachytherapy, EBRT, RP, or cryotherapy PQRS See PQRS See PQRS See cancer patients 30 or # of patients aged 30 or who underwent a radical prostatectomy as treatment for # of radical prostatectomies for patients aged 30 or # of biopsies where a compliant antibiotic regimen was given # of biopsies where a hospital admission resulted within 30 days of the procedure PQRS See # of low risk prostate cancer patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of prostate cancer PQRS See PQRS See PQRS See cancer patients on active surveillance # of patients with a length of stay > 2 days after radical prostatectomy # of radical prostatectomies where a hospital admission resulted within 30 days of the procedure Non-TRUS biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment Biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment age; patients receiving an alternate form of treatment from those specified; patients that have had prior treatment age; patients that have had prior treatment age; patients that have had prior treatment Prostatectomies performed in patients < 30 years of age; patients that have had prior treatment Evidence-based care Metric of safety of medical care PQRS See Metric of appropriate resource utilization PQRS See PQRS See PQRS See Metric of patientcentered decision making Metric of appropriate resource utilization Metric of safety of medical care Michigan Urological Surgery Improvement Collaborative () QCDR Page 2

Non-PQRS #1 ( QCDR-1): Prostate Biopsy Antibiotic Compliance Prostate Biopsy: Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy Patient safety # of biopsies where a compliant antibiotic regimen was given # of prostate biopsies for patients aged 30 or Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for Evidence-based care Non-PQRS # 2 ( QCDR-2): Unplanned Hospital Admissions within 30 days of TRUS Biopsy Percentage of biopsies where patients aged 30 years and had an unplanned hospital admission within 30 days of biopsy clinical care # of biopsies where a hospital admission resulted within 30 days of the procedure # of prostate biopsies for patients aged 30 or Excludes non-trus biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for Metric of safety of medical care Michigan Urological Surgery Improvement Collaborative () QCDR Page 3

Non-PQRS # 3 ( QCDR-3): Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients Percentage of patients, regardless of age, with a diagnosis of at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of Efficiency and cost reduction # of low risk patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of # of low-risk patients 30 years or receiving brachytherapy, EBRT, RP, or cryotherapy Excludes patients < 30 years of age; patients receiving an alternate form of treatment from those specified; patients that have had prior treatment Metric of appropriate resource utilization Non-PQRS # 4 ( QCDR-4): Prostate Cancer: Proportion of Patients with Low-Risk Prostate Cancer Receiving Active Surveillance Proportion of patients with low-risk receiving active surveillance clinical care # of low-risk patients on active surveillance # of prostate biopsies for patients aged 30 or Excludes patients < 30 years of age; patients that have had prior treatment Metric of patient-centered decision making Michigan Urological Surgery Improvement Collaborative () QCDR Page 4

Non-PQRS # 5 ( QCDR-5): Prostate Cancer: Percentage of Prostate Cancer Cases with a Length of Stay > 2 Days Percentage of radical prostatectomy cases with a length of stay > 2 days clinical care # of patients with a length of stay > 2 days after radical prostatectomy # of patients aged 30 or who underwent a radical prostatectomy as treatment Excludes patients < 30 years of age; patients that have had prior treatment Metric of appropriate resource utilization Non-PQRS # 6 ( QCDR-6): Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy Percentage of patients aged 30 years and who had an unplanned hospital readmission within 30 days of principal procedure clinical care # of radical prostatectomies where a hospital admission resulted within 30 days of the procedure # of radical prostatectomies for patients aged 30 or Excludes prostatectomies performed in patients < 30 years of age; patients that have had prior treatment Metric of safety of medical care Michigan Urological Surgery Improvement Collaborative () QCDR Page 5